{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:28:11Z","timestamp":1762867691451,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb GmbH & Co. KGaA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1218-0","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T07:03:23Z","timestamp":1549263803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-421X","authenticated-orcid":false,"given":"Michael","family":"Duerr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva V.","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas J.","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9on","family":"Bergfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Glander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan R.","family":"Marticorena Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian E.","family":"Althoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingolf","family":"Sack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Brakemeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Halleck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"issue":"5","key":"1218_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/jvh.12148","volume":"21","author":"F Fabrizi","year":"2014","unstructured":"Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: hepatitis C and survival after renal transplant. J Viral Hepat. 2014;21(5):314\u201324.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1218_CR2","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.510290123","volume":"29","author":"P Mathurin","year":"1999","unstructured":"Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257\u201363.","journal-title":"Hepatology"},{"issue":"5","key":"1218_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/01.TP.0000131948.29742.24","volume":"78","author":"A Bruchfeld","year":"2004","unstructured":"Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation. 2004;78(5):745\u201350.","journal-title":"Transplantation"},{"issue":"10","key":"1218_CR4","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1111\/ajt.12835","volume":"14","author":"S Baid-Agrawal","year":"2014","unstructured":"Baid-Agrawal S, Pascual M, Moradpour D, Somasundaram R, Muche M. Hepatitis C virus infection and kidney transplantation in 2014: what's new? Am J Transplant. 2014;14(10):2206\u201320.","journal-title":"Am J Transplant"},{"issue":"3","key":"1218_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2215\/CJN.02930806","volume":"2","author":"NA Terrault","year":"2007","unstructured":"Terrault NA, Adey DB. The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment. Clin J Am Soc Nephrol. 2007;2(3):563\u201375.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"1218_CR6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","volume":"19","author":"F Fabrizi","year":"2012","unstructured":"Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19(9):601\u20137.","journal-title":"J Viral Hepat"},{"issue":"4","key":"1218_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469\u201377.","journal-title":"J Infect Dis"},{"issue":"9286","key":"1218_CR8","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958\u201365.","journal-title":"Lancet"},{"issue":"12","key":"1218_CR9","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1097\/TP.0000000000000847","volume":"99","author":"D Sawinski","year":"2015","unstructured":"Sawinski D, Bloom RD. Novel hepatitis C treatment and the impact on kidney transplantation. Transplantation. 2015;99(12):2458\u201366.","journal-title":"Transplantation"},{"issue":"13","key":"1218_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195\u2013206.","journal-title":"N Engl J Med"},{"issue":"25","key":"1218_CR11","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405\u201316.","journal-title":"N Engl J Med"},{"issue":"3","key":"1218_CR12","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/ajt.14001","volume":"17","author":"S Kulkarni","year":"2017","unstructured":"Kulkarni S, Kirkiles-Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V, et al. Eculizumab therapy for Chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant. 2017;17(3):682\u201391.","journal-title":"Am J Transplant"},{"issue":"2","key":"1218_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1128\/CVI.00287-08","volume":"16","author":"S Gehring","year":"2009","unstructured":"Gehring S, Gregory SH, Wintermeyer P, Aloman C, Wands JR. Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol. 2009;16(2):163\u201371.","journal-title":"Clin Vaccine Immunol"},{"issue":"4","key":"1218_CR14","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127\u201335.","journal-title":"Hepatology"},{"issue":"3","key":"1218_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"1218_CR16","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430\u201341.","journal-title":"Hepatology"},{"issue":"12","key":"1218_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/cid\/ciw163","volume":"62","author":"AF Luetkemeyer","year":"2016","unstructured":"Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 weeks of Daclatasvir in combination with Sofosbuvir for HIV-HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62(12):1489\u201396.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1218_CR18","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ajt.13620","volume":"16","author":"D Sawinski","year":"2016","unstructured":"Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16(5):1588\u201395.","journal-title":"Am J Transplant"},{"issue":"5","key":"1218_CR19","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/ajt.13518","volume":"16","author":"N Kamar","year":"2016","unstructured":"Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssiere L, et al. Efficacy and safety of Sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16(5):1474\u20139.","journal-title":"Am J Transplant"},{"key":"1218_CR20","doi-asserted-by":"publisher","unstructured":"Eisenberger U, Guberina H, Willuweit K, Bienholz A, Kribben A, Gerken G, et al. Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients. Transplantation. 2017;101(5):980\u20136. \n                    https:\/\/doi.org\/10.1097\/TP.0000000000001414\n                    \n                  .","DOI":"10.1097\/TP.0000000000001414"},{"issue":"4","key":"1218_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2016.12.020","volume":"66","author":"I Fernandez","year":"2017","unstructured":"Fernandez I, Munoz-Gomez R, Pascasio JM, Baliellas C, Polanco N, Esforzado N, et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol. 2017;66(4):718\u201323.","journal-title":"J Hepatol"},{"issue":"2","key":"1218_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.7326\/M16-1205","volume":"166","author":"M Colombo","year":"2017","unstructured":"Colombo M, Aghemo A, Liu H, Zhang J, Dvory-Sobol H, Hyland R, et al. Treatment with Ledipasvir-Sofosbuvir for 12 or 24 weeks in kidney transplant recipients with Chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial. Ann Intern Med. 2017;166(2):109\u201317.","journal-title":"Ann Intern Med"},{"issue":"9","key":"1218_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"1218_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1360-0443.2006.01584.x","volume":"101","author":"D Hasin","year":"2006","unstructured":"Hasin D, Hatzenbuehler ML, Keyes K, Ogburn E. Substance use disorders: diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV) and international classification of diseases, tenth edition (ICD-10). Addiction. 2006;101(Suppl 1):59\u201375.","journal-title":"Addiction"},{"issue":"1","key":"1218_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.14107","volume":"17","author":"A Loupy","year":"2017","unstructured":"Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017;17(1):28\u201341.","journal-title":"Am J Transplant"},{"issue":"9","key":"1218_CR26","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1111\/ajt.12850","volume":"14","author":"A Sharif","year":"2014","unstructured":"Sharif A, Hecking M, de Vries AP, Porrini E, Hornum M, Rasoul-Rockenschaub S, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992\u20132000.","journal-title":"Am J Transplant"},{"issue":"12","key":"1218_CR27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.2337\/diacare.21.12.2191","volume":"21","author":"JC Levy","year":"1998","unstructured":"Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191\u20132.","journal-title":"Diabetes Care"},{"issue":"7","key":"1218_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.jvir.2010.01.011","volume":"21","author":"S Gupta","year":"2010","unstructured":"Gupta S, Wallace MJ, Cardella JF, Kundu S, Miller DL, Rose SC, et al. Quality improvement guidelines for percutaneous needle biopsy. J Vasc Interv Radiol. 2010;21(7):969\u201375.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"1218_CR29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/00000478-199512000-00007","volume":"19","author":"KP Batts","year":"1995","unstructured":"Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19(12):1409\u201317.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1218_CR30","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","volume":"13","author":"PJ Scheuer","year":"1991","unstructured":"Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13(3):372\u20134.","journal-title":"J Hepatol"},{"issue":"2","key":"1218_CR31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"CT Wai","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518\u201326.","journal-title":"Hepatology"},{"issue":"7\u20138","key":"1218_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.clinbiochem.2015.12.017","volume":"49","author":"MJ Andres-Otero","year":"2016","unstructured":"Andres-Otero MJ, De-Blas-Giral I, Puente-Lanzarote JJ, Serrano-Aullo T, Morandeira MJ, Lorente S, et al. Multiple approaches to assess fourteen non-invasive serum indexes for the diagnosis of liver fibrosis in chronic hepatitis C patients. Clin Biochem. 2016;49(7\u20138):560\u20135.","journal-title":"Clin Biochem"},{"issue":"6","key":"1218_CR33","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43(6):1317\u201325.","journal-title":"Hepatology"},{"issue":"22","key":"1218_CR34","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134\u201346.","journal-title":"N Engl J Med"},{"issue":"3","key":"1218_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s12072-015-9624-2","volume":"9","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Kanda T, Matsumura H, Moriyama M, Yokosuka O, Omata M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol Int. 2015;9(3):424\u201330.","journal-title":"Hepatol Int"},{"issue":"7","key":"1218_CR36","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1097\/TP.0000000000001618","volume":"101","author":"M Lubetzky","year":"2017","unstructured":"Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, Ajaimy M, et al. Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation. 2017;101(7):1704\u201310.","journal-title":"Transplantation"},{"issue":"5","key":"1218_CR37","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/TP.0000000000001414","volume":"101","author":"U Eisenberger","year":"2017","unstructured":"Eisenberger U, Guberina H, Willuweit K, Bienholz A, Kribben A, Gerken G, et al. Successful treatment of Chronic hepatitis C virus infection with Sofosbuvir and Ledipasvir in renal transplant recipients. Transplantation. 2017;101(5):980\u20136.","journal-title":"Transplantation"},{"issue":"5","key":"1218_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"CHZ Siederdissen","year":"2016","unstructured":"Siederdissen CHZ, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-drug interactions with novel all Oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1\u20132","key":"1218_CR39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2119\/2006-00057.Fujita","volume":"13","author":"N Fujita","year":"2007","unstructured":"Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007;13(1\u20132):97\u2013104.","journal-title":"Mol Med"},{"issue":"7","key":"1218_CR40","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","volume":"25","author":"L Arcaini","year":"2014","unstructured":"Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJ, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404\u201310.","journal-title":"Ann Oncol"},{"issue":"8","key":"1218_CR41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/17474086.2017.1349607","volume":"10","author":"M Visentini","year":"2017","unstructured":"Visentini M, Fiorilli M, Casato M. From the pathogenesis to the cure of indolent B-cell lymphoproliferative disorders associated with hepatitis C virus infection: which role for direct-acting antivirals? Expert Rev Hematol. 2017;10(8):719\u201327.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"1218_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14218\/JCTH.2015.00051","volume":"4","author":"D Kralj","year":"2016","unstructured":"Kralj D, Virovic Jukic L, Stojsavljevic S, Duvnjak M, Smolic M, Curcic IB. Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol. 2016;4(1):66\u201375.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"1218_CR43","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","volume":"102","author":"T Kawaguchi","year":"2007","unstructured":"Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"1218_CR44","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/j.1572-0241.2008.02007.x","volume":"103","author":"A Aytaman","year":"2008","unstructured":"Aytaman A, McFarlane SI. Uncovering glucose abnormalities in people with hepatitis C infection: should oral glucose tolerance test become a standard of care? Am J Gastroenterol. 2008;103(8):1941\u20133.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1218_CR45","first-page":"1105","volume":"377","author":"DS Goldberg","year":"2017","unstructured":"Goldberg DS, Abt PL, Reese PP, Investigators TT. Transplanting HCV-infected kidneys into uninfected recipients. N Engl J Med. 2017;377(11):1105.","journal-title":"N Engl J Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1218-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1218-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T19:18:33Z","timestamp":1580757513000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1218-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1218-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"10 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent. The study protocols were conducted in compliance with German law and approved by the independent ethics committee at the \u201cLandesamt f\u00fcr Gesundheit und Soziales\u201d of the state Berlin (approval number: 15\/0446EK15) and the Federal Institute for Drugs and Medical Devices (approval number: 4040892).All procedures followed in the trials were in accordance with the Declaration of Helsinki, the International Conference on Harmonization and Good Clinical Practice guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Michael Duerr received a travel grant and speakers honoraria from BMS, Novartis, Roche and Astellas.Eva V. Schrezenmeier has no conflict of interest to declare.Lukas L. Lehner has no conflict of interest to declare.Leon Bergfeld has no conflict of interest to declare.Petra Glander has no conflict of interest to declare.Stephan R. Marticorena has no conflict of interest to declare.Christian E. Althoff has no conflict of interest to declare.Ingolf Sack has no conflict of interest to declare.Susanne Brakemeier has no conflict of interest to declare.Kai-Uwe Eckardt has no conflict of interest to declare.Klemens Budde has received research funds and\/or honoraria from Abbvie, Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Genentech, Hexal, Novartis, Otsuka, Pfizer, Roche, Shire, Siemens, and Veloxis Pharma.Fabian Hallck has no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"36"}}